search
Back to results

Exacerbation Study (INVIGORATE)

Primary Purpose

Chronic Obstructive Pulmonary Disease

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Indacaterol 150 µg
Tiotropium
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease focused on measuring Indacaterol, Tiotropium, COPD

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female adults aged ≥40 years, who have signed an Informed Consent form prior to initiation of any study-related procedure

  • Patients diagnosed with COPD at age 40 and over and with a current diagnosis of severe COPD and including:

    1. Smoking history of at least 10 pack years, both current and ex-smokers are eligible
    2. A documented history of at least 1 moderate or severe exacerbation in the previous 12 months

Exclusion Criteria:

  • Patients who have received systemic corticosteroids and/or antibiotics for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period
  • Patients who have had a respiratory tract infection within 6 weeks prior to screening
  • Patients with concomitant pulmonary disease
  • Patients with a history of asthma
  • Patients with diabetes Type I or uncontrolled diabetes Type II
  • Any patient with lung cancer or a history of lung cancer
  • Patients with a history of certain cardiovascular comorbid conditions

Other protocol-defined inclusion/exclusion criteria may apply

Sites / Locations

  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Indacaterol

Tiotropium

Arm Description

Indacaterol 150 µg o.d. delivered via single-dose dry powder inhaler (SDDPI)

Tiotropium 18 µg o.d. delivered via the handihaler®

Outcomes

Primary Outcome Measures

Trough Forced Expiratory Volume in 1 Second (FEV1).
The primary objective of the study was to demonstrate the non-inferiority of indacaterol vs. tiotropium with respect to 24 hour post dose (trough) FEV1 after 12 weeks of treatment in patients with severe COPD. Trough FEV1 was defined as the average of the 23 hours 10 min and the 23 hours 45 min post dose values. Trough FEV1 was analyzed using a mixed model for the PPS-S. The model contained treatment as a fixed effect with the baseline FEV1, FEV1 prior to inhalation and FEV1 15 min post-inhalation of salbutamol/albuterol (components of SABA reversibility at Visit 2), FEV1 prior to inhalation and FEV1 60 min post-inhalation of ipratropium (components of anti-cholinergic reversibility at Visit 3) as covariates. Smoking history (current or ex-smoker) was included as a factor in the model.

Secondary Outcome Measures

Rate of COPD Exacerbations
COPD exacerbations were defined as :Worsening of 2 or more major symptoms for at least 2 consecutive days: dyspnea; sputum volume; suputum purulence AND requiring treatment with systemic corticosteroids and/or antibiotics OR Worsening of any 1 major symptom together with any 1 of the following minor symptoms for at least 2 consecutive days: Sore throat; colds; fever without other cause; increased cough; increase wheeze AND requiring treatment with systemic glucocorticosteroids and/or antibiotics. The rate was analyzed using a linear model assuming a negative binomial distribution for the PPS-E. The time at risk for a patient was defined as the length of time the patient was in the study and the log(length of time in the study) was used as the offset variable in the model.

Full Information

First Posted
February 15, 2009
Last Updated
September 16, 2013
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00845728
Brief Title
Exacerbation Study
Acronym
INVIGORATE
Official Title
A Phase IIIb Multicenter, 52 Week Treatment, Randomized, Blinded, Double Dummy, Parallel Group Efficacy Study Comparing the Effect of Inhaled Indacaterol 150 µg o.d. vs Inhaled Tiotropium 18 µg o.d. on Lung Function, Rate of Exacerbations and Related Outcomes in Patients With COPD
Study Type
Interventional

2. Study Status

Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
July 2012 (Actual)
Study Completion Date
July 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease
Keywords
Indacaterol, Tiotropium, COPD

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
3439 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Indacaterol
Arm Type
Experimental
Arm Description
Indacaterol 150 µg o.d. delivered via single-dose dry powder inhaler (SDDPI)
Arm Title
Tiotropium
Arm Type
Active Comparator
Arm Description
Tiotropium 18 µg o.d. delivered via the handihaler®
Intervention Type
Drug
Intervention Name(s)
Indacaterol 150 µg
Intervention Description
Indacaterol 150 µg o.d. delivered via SDDPI
Intervention Type
Drug
Intervention Name(s)
Tiotropium
Intervention Description
Tiotropium 18 µg o.d. delivered via handihaler®
Primary Outcome Measure Information:
Title
Trough Forced Expiratory Volume in 1 Second (FEV1).
Description
The primary objective of the study was to demonstrate the non-inferiority of indacaterol vs. tiotropium with respect to 24 hour post dose (trough) FEV1 after 12 weeks of treatment in patients with severe COPD. Trough FEV1 was defined as the average of the 23 hours 10 min and the 23 hours 45 min post dose values. Trough FEV1 was analyzed using a mixed model for the PPS-S. The model contained treatment as a fixed effect with the baseline FEV1, FEV1 prior to inhalation and FEV1 15 min post-inhalation of salbutamol/albuterol (components of SABA reversibility at Visit 2), FEV1 prior to inhalation and FEV1 60 min post-inhalation of ipratropium (components of anti-cholinergic reversibility at Visit 3) as covariates. Smoking history (current or ex-smoker) was included as a factor in the model.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Rate of COPD Exacerbations
Description
COPD exacerbations were defined as :Worsening of 2 or more major symptoms for at least 2 consecutive days: dyspnea; sputum volume; suputum purulence AND requiring treatment with systemic corticosteroids and/or antibiotics OR Worsening of any 1 major symptom together with any 1 of the following minor symptoms for at least 2 consecutive days: Sore throat; colds; fever without other cause; increased cough; increase wheeze AND requiring treatment with systemic glucocorticosteroids and/or antibiotics. The rate was analyzed using a linear model assuming a negative binomial distribution for the PPS-E. The time at risk for a patient was defined as the length of time the patient was in the study and the log(length of time in the study) was used as the offset variable in the model.
Time Frame
52 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female adults aged ≥40 years, who have signed an Informed Consent form prior to initiation of any study-related procedure Patients diagnosed with COPD at age 40 and over and with a current diagnosis of severe COPD and including: Smoking history of at least 10 pack years, both current and ex-smokers are eligible A documented history of at least 1 moderate or severe exacerbation in the previous 12 months Exclusion Criteria: Patients who have received systemic corticosteroids and/or antibiotics for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period Patients who have had a respiratory tract infection within 6 weeks prior to screening Patients with concomitant pulmonary disease Patients with a history of asthma Patients with diabetes Type I or uncontrolled diabetes Type II Any patient with lung cancer or a history of lung cancer Patients with a history of certain cardiovascular comorbid conditions Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Capital Federal
State/Province
Buenos Aires
ZIP/Postal Code
C1424BSF
Country
Argentina
Facility Name
Novartis Investigative Site
City
Mar del Plata
State/Province
Buenos Aires
ZIP/Postal Code
7600
Country
Argentina
Facility Name
Novartis Investigative Site
City
Pilar
State/Province
Buenos Aires
ZIP/Postal Code
B1629AHJ
Country
Argentina
Facility Name
Novartis Investigative Site
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
C2000DSR
Country
Argentina
Facility Name
Novartis Investigative Site
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000AYW
Country
Argentina
Facility Name
Novartis Investigative Site
City
San Miguel de Tucuman
State/Province
Tucuman
ZIP/Postal Code
4000
Country
Argentina
Facility Name
Novartis Investigative Site
City
Buenos Aires
ZIP/Postal Code
5000
Country
Argentina
Facility Name
Novartis Investigative Site
City
Buenos Aires
ZIP/Postal Code
B1842DID
Country
Argentina
Facility Name
Novartis Investigative Site
City
Buenos Aires
ZIP/Postal Code
C1122AAK
Country
Argentina
Facility Name
Novartis Investigative Site
City
Buenos Aires
ZIP/Postal Code
C1125ABE
Country
Argentina
Facility Name
Novartis Investigative Site
City
Buenos aires
ZIP/Postal Code
C1221ADC
Country
Argentina
Facility Name
Novartis Investigative Site
City
Buenos Aires
ZIP/Postal Code
C1426ABP
Country
Argentina
Facility Name
Novartis Investigative Site
City
Buenos Aires
Country
Argentina
Facility Name
Novartis Investigative Site
City
Mendoza
ZIP/Postal Code
M5500CCG
Country
Argentina
Facility Name
Novartis Investigative Site
City
Bankstown
State/Province
New South Wales
ZIP/Postal Code
2200
Country
Australia
Facility Name
Novartis Investigative Site
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Facility Name
Novartis Investigative Site
City
Daw Park
State/Province
South Australia
ZIP/Postal Code
5041
Country
Australia
Facility Name
Novartis Investigative Site
City
Heidelberg
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia
Facility Name
Novartis Investigative Site
City
Parkville
State/Province
Victoria
ZIP/Postal Code
3050
Country
Australia
Facility Name
Novartis Investigative Site
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
Novartis Investigative Site
City
Tauranga, New Zealand
ZIP/Postal Code
3001
Country
Australia
Facility Name
Novartis Investigative Site
City
Feldbach
ZIP/Postal Code
8330
Country
Austria
Facility Name
Novartis Investigative Site
City
Grieskirchen
ZIP/Postal Code
4710
Country
Austria
Facility Name
Novartis Investigative Site
City
Gänserndorf
ZIP/Postal Code
2230
Country
Austria
Facility Name
Novartis Investigative Site
City
Hallein
ZIP/Postal Code
5400
Country
Austria
Facility Name
Novartis Investigative Site
City
Linz
ZIP/Postal Code
4020
Country
Austria
Facility Name
Novartis Investigative Site
City
Perg
ZIP/Postal Code
4320
Country
Austria
Facility Name
Novartis Investigative Site
City
Zwettl
ZIP/Postal Code
3910
Country
Austria
Facility Name
Novartis Investigative Site
City
Aalst
ZIP/Postal Code
9300
Country
Belgium
Facility Name
Novartis Investigative Site
City
Antwerpen
ZIP/Postal Code
2020
Country
Belgium
Facility Name
Novartis Investigative Site
City
Bruxelles
ZIP/Postal Code
1000
Country
Belgium
Facility Name
Novartis Investigative Site
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Facility Name
Novartis Investigative Site
City
Duffel
ZIP/Postal Code
2570
Country
Belgium
Facility Name
Novartis Investigative Site
City
Eupen
ZIP/Postal Code
4700
Country
Belgium
Facility Name
Novartis Investigative Site
City
Framerie
ZIP/Postal Code
7080
Country
Belgium
Facility Name
Novartis Investigative Site
City
Geraardsbergen
ZIP/Postal Code
9500
Country
Belgium
Facility Name
Novartis Investigative Site
City
Gilly
ZIP/Postal Code
6060
Country
Belgium
Facility Name
Novartis Investigative Site
City
Godinne
ZIP/Postal Code
5530
Country
Belgium
Facility Name
Novartis Investigative Site
City
Gozée
ZIP/Postal Code
6534
Country
Belgium
Facility Name
Novartis Investigative Site
City
Herentals
ZIP/Postal Code
2200
Country
Belgium
Facility Name
Novartis Investigative Site
City
Jambes
ZIP/Postal Code
5100
Country
Belgium
Facility Name
Novartis Investigative Site
City
Jette
ZIP/Postal Code
1090
Country
Belgium
Facility Name
Novartis Investigative Site
City
Kortrijk
ZIP/Postal Code
8500
Country
Belgium
Facility Name
Novartis Investigative Site
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Novartis Investigative Site
City
Liege
ZIP/Postal Code
4000
Country
Belgium
Facility Name
Novartis Investigative Site
City
Liège
ZIP/Postal Code
4000
Country
Belgium
Facility Name
Novartis Investigative Site
City
Malmedy
ZIP/Postal Code
4960
Country
Belgium
Facility Name
Novartis Investigative Site
City
Menen
ZIP/Postal Code
8930
Country
Belgium
Facility Name
Novartis Investigative Site
City
Montigny-le-tilleul
ZIP/Postal Code
6110
Country
Belgium
Facility Name
Novartis Investigative Site
City
Namur
ZIP/Postal Code
5000
Country
Belgium
Facility Name
Novartis Investigative Site
City
Oostende
ZIP/Postal Code
8400
Country
Belgium
Facility Name
Novartis Investigative Site
City
Turnhout
ZIP/Postal Code
2300
Country
Belgium
Facility Name
Novartis Investigative Site
City
Goiania
State/Province
GO
ZIP/Postal Code
74605-050
Country
Brazil
Facility Name
Novartis Investigative Site
City
Juiz de Fora
State/Province
MG
ZIP/Postal Code
36036-110
Country
Brazil
Facility Name
Novartis Investigative Site
City
Rio de Janeiro
State/Province
RJ
ZIP/Postal Code
22271-110
Country
Brazil
Facility Name
Novartis Investigative Site
City
Caxias do Sul
State/Province
RS
ZIP/Postal Code
95070-560
Country
Brazil
Facility Name
Novartis Investigative Site
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90020-090
Country
Brazil
Facility Name
Novartis Investigative Site
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90610-000
Country
Brazil
Facility Name
Novartis Investigative Site
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90880-480
Country
Brazil
Facility Name
Novartis Investigative Site
City
São Paulo
State/Province
SP
ZIP/Postal Code
04023-062
Country
Brazil
Facility Name
Novartis Investigative Site
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4N1
Country
Canada
Facility Name
Novartis Investigative Site
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2V 1P9
Country
Canada
Facility Name
Novartis Investigative Site
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2B7
Country
Canada
Facility Name
Novartis Investigative Site
City
Kelowna
State/Province
British Columbia
ZIP/Postal Code
V1Y 1E4
Country
Canada
Facility Name
Novartis Investigative Site
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 3J5
Country
Canada
Facility Name
Novartis Investigative Site
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3C 0N2
Country
Canada
Facility Name
Novartis Investigative Site
City
Moncton
State/Province
New Brunswick
ZIP/Postal Code
E1G 1A7
Country
Canada
Facility Name
Novartis Investigative Site
City
Burlington
State/Province
Ontario
ZIP/Postal Code
L7N 3V2
Country
Canada
Facility Name
Novartis Investigative Site
City
Mississauga
State/Province
Ontario
ZIP/Postal Code
L5B 4A9
Country
Canada
Facility Name
Novartis Investigative Site
City
Newmarket
State/Province
Ontario
ZIP/Postal Code
L3Y 5G8
Country
Canada
Facility Name
Novartis Investigative Site
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y 4G2
Country
Canada
Facility Name
Novartis Investigative Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G1N8
Country
Canada
Facility Name
Novartis Investigative Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5T 3A9
Country
Canada
Facility Name
Novartis Investigative Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M6H 3M2
Country
Canada
Facility Name
Novartis Investigative Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2L 2W5
Country
Canada
Facility Name
Novartis Investigative Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2L 4M1
Country
Canada
Facility Name
Novartis Investigative Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2X 2P4
Country
Canada
Facility Name
Novartis Investigative Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4J 1C5
Country
Canada
Facility Name
Novartis Investigative Site
City
Sainte-Foy
State/Province
Quebec
ZIP/Postal Code
G1V 4G5
Country
Canada
Facility Name
Novartis Investigative Site
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1H 4J6
Country
Canada
Facility Name
Novartis Investigative Site
City
Shijiazhuang
State/Province
Hebei
ZIP/Postal Code
050000
Country
China
Facility Name
Novartis Investigative Site
City
Changsha City
State/Province
Hunan
ZIP/Postal Code
410011
Country
China
Facility Name
Novartis Investigative Site
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410003
Country
China
Facility Name
Novartis Investigative Site
City
Shengyang
State/Province
Liaoning
ZIP/Postal Code
110016
Country
China
Facility Name
Novartis Investigative Site
City
Xi'an
State/Province
Shanxi
ZIP/Postal Code
710032
Country
China
Facility Name
Novartis Investigative Site
City
Xi'an
State/Province
Shanxi
ZIP/Postal Code
710061
Country
China
Facility Name
Novartis Investigative Site
City
Beijing
ZIP/Postal Code
100020
Country
China
Facility Name
Novartis Investigative Site
City
Beijing
ZIP/Postal Code
100034
Country
China
Facility Name
Novartis Investigative Site
City
Chongqing
ZIP/Postal Code
400037
Country
China
Facility Name
Novartis Investigative Site
City
Shanghai
ZIP/Postal Code
200025
Country
China
Facility Name
Novartis Investigative Site
City
Shen Yang
ZIP/Postal Code
110001
Country
China
Facility Name
Novartis Investigative Site
City
Barranquilla
Country
Colombia
Facility Name
Novartis Investigative Site
City
Bogotá
Country
Colombia
Facility Name
Novartis Investigative Site
City
Medellín
Country
Colombia
Facility Name
Novartis Investigative Site
City
San Francisco de Asís
Country
Costa Rica
Facility Name
Novartis Investigative Site
City
San Jose
Country
Costa Rica
Facility Name
Novartis Investigative Site
City
Kyjov
State/Province
CZE
ZIP/Postal Code
697 70
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Beroun
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Ceske Budejovice
ZIP/Postal Code
370 87
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Cesky Krumlov
ZIP/Postal Code
381 01
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Cvikov
ZIP/Postal Code
471 54
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Karlovy Vary
ZIP/Postal Code
360 06
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Karlovy Vary
ZIP/Postal Code
360 66
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Kurim
ZIP/Postal Code
66434
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Novy Jicin
ZIP/Postal Code
741 01
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Ostrava - Hrabuvka
ZIP/Postal Code
70030
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Ostrava
ZIP/Postal Code
70030
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Praha 6
ZIP/Postal Code
169 00
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Prerov
ZIP/Postal Code
75000
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Rokycany
ZIP/Postal Code
337 22
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Rudna
ZIP/Postal Code
25219
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Strakonice
ZIP/Postal Code
38601
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Teplice
ZIP/Postal Code
415 01
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Zatec
ZIP/Postal Code
438 01
Country
Czech Republic
Facility Name
Novartis Investigative Site
City
Aalborg
ZIP/Postal Code
DK-9100
Country
Denmark
Facility Name
Novartis Investigative Site
City
Copenhagen NV
ZIP/Postal Code
DK-2400
Country
Denmark
Facility Name
Novartis Investigative Site
City
Hellerup
ZIP/Postal Code
DK-2900
Country
Denmark
Facility Name
Novartis Investigative Site
City
Helsingor
ZIP/Postal Code
DK-3000
Country
Denmark
Facility Name
Novartis Investigative Site
City
Hvidovre
ZIP/Postal Code
DK-2650
Country
Denmark
Facility Name
Novartis Investigative Site
City
Odense C
ZIP/Postal Code
DK-5000
Country
Denmark
Facility Name
Novartis Investigative Site
City
Århus
ZIP/Postal Code
DK-8000
Country
Denmark
Facility Name
Novartis Investigative Site
City
Rakvere
ZIP/Postal Code
44310
Country
Estonia
Facility Name
Novartis Investigative Site
City
Tallinn
ZIP/Postal Code
13619
Country
Estonia
Facility Name
Novartis Investigative Site
City
Tartu
ZIP/Postal Code
51014
Country
Estonia
Facility Name
Novartis Investigative Site
City
Helsinki
ZIP/Postal Code
00029
Country
Finland
Facility Name
Novartis Investigative Site
City
HUS
ZIP/Postal Code
00029
Country
Finland
Facility Name
Novartis Investigative Site
City
Jyvaskyla
ZIP/Postal Code
40100
Country
Finland
Facility Name
Novartis Investigative Site
City
Pori
ZIP/Postal Code
FIN-28500
Country
Finland
Facility Name
Novartis Investigative Site
City
Porvoo
ZIP/Postal Code
FIN-06200
Country
Finland
Facility Name
Novartis Investigative Site
City
Tampere
ZIP/Postal Code
FIN-33521
Country
Finland
Facility Name
Novartis Investigative Site
City
Turku
ZIP/Postal Code
FIN-20100
Country
Finland
Facility Name
Novartis Investigative Site
City
Beuvry
ZIP/Postal Code
62660
Country
France
Facility Name
Novartis Investigative Site
City
Bourges
ZIP/Postal Code
18000
Country
France
Facility Name
Novartis Investigative Site
City
Ferolles-Attily
ZIP/Postal Code
77150
Country
France
Facility Name
Novartis Investigative Site
City
Lyon cedex 04
ZIP/Postal Code
69317
Country
France
Facility Name
Novartis Investigative Site
City
Montpellier
ZIP/Postal Code
34059
Country
France
Facility Name
Novartis Investigative Site
City
Nantes
ZIP/Postal Code
44000
Country
France
Facility Name
Novartis Investigative Site
City
Nice Cedex 1
ZIP/Postal Code
06602
Country
France
Facility Name
Novartis Investigative Site
City
Ollioules Cedex
ZIP/Postal Code
83192
Country
France
Facility Name
Novartis Investigative Site
City
Paris
ZIP/Postal Code
75006
Country
France
Facility Name
Novartis Investigative Site
City
Perpignan Cedex
ZIP/Postal Code
66025
Country
France
Facility Name
Novartis Investigative Site
City
Pessac
ZIP/Postal Code
33604
Country
France
Facility Name
Novartis Investigative Site
City
Reims
ZIP/Postal Code
51092
Country
France
Facility Name
Novartis Investigative Site
City
St Michel
ZIP/Postal Code
16470
Country
France
Facility Name
Novartis Investigative Site
City
Vandoeuvre les Nancy
ZIP/Postal Code
54511
Country
France
Facility Name
Novartis Investigative Site
City
Bad Woerishofen
ZIP/Postal Code
86825
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
10367
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
10969
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
12043
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
12687
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
13057
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
13086
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
13507
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
13581
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
14050
Country
Germany
Facility Name
Novartis Investigative Site
City
Bonn
ZIP/Postal Code
53119
Country
Germany
Facility Name
Novartis Investigative Site
City
Bonn
ZIP/Postal Code
53123
Country
Germany
Facility Name
Novartis Investigative Site
City
Borstel
ZIP/Postal Code
23845
Country
Germany
Facility Name
Novartis Investigative Site
City
Dachau
ZIP/Postal Code
85221
Country
Germany
Facility Name
Novartis Investigative Site
City
Euskirchen
ZIP/Postal Code
53879
Country
Germany
Facility Name
Novartis Investigative Site
City
Frankfurt
ZIP/Postal Code
60596
Country
Germany
Facility Name
Novartis Investigative Site
City
Fürstenwalde/Spree
ZIP/Postal Code
15517
Country
Germany
Facility Name
Novartis Investigative Site
City
Güstrow
ZIP/Postal Code
18273
Country
Germany
Facility Name
Novartis Investigative Site
City
Hamburg
ZIP/Postal Code
20354
Country
Germany
Facility Name
Novartis Investigative Site
City
Hamburg
ZIP/Postal Code
20357
Country
Germany
Facility Name
Novartis Investigative Site
City
Hamburg
ZIP/Postal Code
22299
Country
Germany
Facility Name
Novartis Investigative Site
City
Hamburg
ZIP/Postal Code
22305
Country
Germany
Facility Name
Novartis Investigative Site
City
Hoyerswerda
ZIP/Postal Code
02977
Country
Germany
Facility Name
Novartis Investigative Site
City
Landsberg
ZIP/Postal Code
86899
Country
Germany
Facility Name
Novartis Investigative Site
City
Leipzig
ZIP/Postal Code
04207
Country
Germany
Facility Name
Novartis Investigative Site
City
Mainz
ZIP/Postal Code
D-55101
Country
Germany
Facility Name
Novartis Investigative Site
City
Marburg
ZIP/Postal Code
35037
Country
Germany
Facility Name
Novartis Investigative Site
City
Muenchen
ZIP/Postal Code
80331
Country
Germany
Facility Name
Novartis Investigative Site
City
Muenchen
ZIP/Postal Code
80539
Country
Germany
Facility Name
Novartis Investigative Site
City
Muenchen
ZIP/Postal Code
81243
Country
Germany
Facility Name
Novartis Investigative Site
City
Muenchen
ZIP/Postal Code
81677
Country
Germany
Facility Name
Novartis Investigative Site
City
München
ZIP/Postal Code
80335
Country
Germany
Facility Name
Novartis Investigative Site
City
Neu-Ulm
ZIP/Postal Code
89231
Country
Germany
Facility Name
Novartis Investigative Site
City
Neumünster
ZIP/Postal Code
24534
Country
Germany
Facility Name
Novartis Investigative Site
City
Neuss
ZIP/Postal Code
41462
Country
Germany
Facility Name
Novartis Investigative Site
City
Oranienburg
ZIP/Postal Code
16515
Country
Germany
Facility Name
Novartis Investigative Site
City
Radebeul
ZIP/Postal Code
01445
Country
Germany
Facility Name
Novartis Investigative Site
City
Ratingen
ZIP/Postal Code
40878
Country
Germany
Facility Name
Novartis Investigative Site
City
Rüdersdorf
ZIP/Postal Code
15562
Country
Germany
Facility Name
Novartis Investigative Site
City
Teterow
ZIP/Postal Code
17166
Country
Germany
Facility Name
Novartis Investigative Site
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Facility Name
Novartis Investigative Site
City
Wedel
ZIP/Postal Code
22880
Country
Germany
Facility Name
Novartis Investigative Site
City
Witten
ZIP/Postal Code
58452
Country
Germany
Facility Name
Novartis Investigative Site
City
Budapest
ZIP/Postal Code
1125
Country
Hungary
Facility Name
Novartis Investigative Site
City
Cegled
ZIP/Postal Code
2700
Country
Hungary
Facility Name
Novartis Investigative Site
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Facility Name
Novartis Investigative Site
City
Deszk
ZIP/Postal Code
6772
Country
Hungary
Facility Name
Novartis Investigative Site
City
Mosonmagyarovar
ZIP/Postal Code
9200
Country
Hungary
Facility Name
Novartis Investigative Site
City
Nyiregyhaza
ZIP/Postal Code
4400
Country
Hungary
Facility Name
Novartis Investigative Site
City
Sopron
ZIP/Postal Code
9400
Country
Hungary
Facility Name
Novartis Investigative Site
City
Szarvas
ZIP/Postal Code
5540
Country
Hungary
Facility Name
Novartis Investigative Site
City
Tatabanya
ZIP/Postal Code
2800
Country
Hungary
Facility Name
Novartis Investigative Site
City
Torokbalint
ZIP/Postal Code
2045
Country
Hungary
Facility Name
Novartis Investigative Site
City
Reykjavik
ZIP/Postal Code
IS-109
Country
Iceland
Facility Name
Novartis Investigative Site
City
Hyderabad
State/Province
Andhra Pradesh
ZIP/Postal Code
500004
Country
India
Facility Name
Novartis Investigative Site
City
Hyderabad
State/Province
Andhra Pradesh
ZIP/Postal Code
500012
Country
India
Facility Name
Novartis Investigative Site
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110029
Country
India
Facility Name
Novartis Investigative Site
City
Ahmedabad
State/Province
Gujrat-India
ZIP/Postal Code
380054
Country
India
Facility Name
Novartis Investigative Site
City
Ahmedabad
State/Province
Gujrat
ZIP/Postal Code
380009
Country
India
Facility Name
Novartis Investigative Site
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560 002
Country
India
Facility Name
Novartis Investigative Site
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560002
Country
India
Facility Name
Novartis Investigative Site
City
Mangalore
State/Province
Karnataka
ZIP/Postal Code
575001
Country
India
Facility Name
Novartis Investigative Site
City
Calicut
State/Province
Kerala
ZIP/Postal Code
673008
Country
India
Facility Name
Novartis Investigative Site
City
Trivandrum
State/Province
Kerala
ZIP/Postal Code
695011
Country
India
Facility Name
Novartis Investigative Site
City
Indore
State/Province
Madhya Pradesh
ZIP/Postal Code
452001
Country
India
Facility Name
Novartis Investigative Site
City
Noida
State/Province
New Delhi
ZIP/Postal Code
201301
Country
India
Facility Name
Novartis Investigative Site
City
Jaipur
State/Province
Rajasthan
ZIP/Postal Code
302023
Country
India
Facility Name
Novartis Investigative Site
City
Coimbatore
State/Province
Tamil Nadu
ZIP/Postal Code
641 002
Country
India
Facility Name
Novartis Investigative Site
City
Vellore
State/Province
Tamil Nadu
ZIP/Postal Code
632004
Country
India
Facility Name
Novartis Investigative Site
City
Nagpur - Maharashtra
ZIP/Postal Code
440012
Country
India
Facility Name
Novartis Investigative Site
City
Nagpur - Maharastra
ZIP/Postal Code
400 012
Country
India
Facility Name
Novartis Investigative Site
City
Panjim
ZIP/Postal Code
403002
Country
India
Facility Name
Novartis Investigative Site
City
Ashkelon
ZIP/Postal Code
78278
Country
Israel
Facility Name
Novartis Investigative Site
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Facility Name
Novartis Investigative Site
City
Ramat Gan
ZIP/Postal Code
52621
Country
Israel
Facility Name
Novartis Investigative Site
City
Rehovot
ZIP/Postal Code
76100
Country
Israel
Facility Name
Novartis Investigative Site
City
Tel-Aviv
ZIP/Postal Code
64239
Country
Israel
Facility Name
Novartis Investigative Site
City
Acquaviva delle Fonti
State/Province
BA
ZIP/Postal Code
70021
Country
Italy
Facility Name
Novartis Investigative Site
City
Bari
State/Province
BA
ZIP/Postal Code
70124
Country
Italy
Facility Name
Novartis Investigative Site
City
Bergamo
State/Province
BG
ZIP/Postal Code
24128
Country
Italy
Facility Name
Novartis Investigative Site
City
Brescia
State/Province
BS
ZIP/Postal Code
25127
Country
Italy
Facility Name
Novartis Investigative Site
City
Catanzaro
State/Province
CZ
ZIP/Postal Code
88100
Country
Italy
Facility Name
Novartis Investigative Site
City
Cona
State/Province
FE
ZIP/Postal Code
44100
Country
Italy
Facility Name
Novartis Investigative Site
City
Cassino
State/Province
FR
ZIP/Postal Code
03043
Country
Italy
Facility Name
Novartis Investigative Site
City
Genova
State/Province
GE
ZIP/Postal Code
16132
Country
Italy
Facility Name
Novartis Investigative Site
City
Milano
State/Province
MI
ZIP/Postal Code
20126
Country
Italy
Facility Name
Novartis Investigative Site
City
Milano
State/Province
MI
ZIP/Postal Code
20142
Country
Italy
Facility Name
Novartis Investigative Site
City
Milano
State/Province
MI
ZIP/Postal Code
20157
Country
Italy
Facility Name
Novartis Investigative Site
City
Modena
State/Province
MO
ZIP/Postal Code
41100
Country
Italy
Facility Name
Novartis Investigative Site
City
Palermo
State/Province
PA
ZIP/Postal Code
90146
Country
Italy
Facility Name
Novartis Investigative Site
City
Pordenone
State/Province
PN
ZIP/Postal Code
33170
Country
Italy
Facility Name
Novartis Investigative Site
City
Prato
State/Province
PO
ZIP/Postal Code
59100
Country
Italy
Facility Name
Novartis Investigative Site
City
Parma
State/Province
PR
ZIP/Postal Code
43100
Country
Italy
Facility Name
Novartis Investigative Site
City
Roma
State/Province
RM
ZIP/Postal Code
00133
Country
Italy
Facility Name
Novartis Investigative Site
City
Roma
State/Province
RM
ZIP/Postal Code
00161
Country
Italy
Facility Name
Novartis Investigative Site
City
Roma
State/Province
RM
ZIP/Postal Code
00163
Country
Italy
Facility Name
Novartis Investigative Site
City
Roma
State/Province
RM
ZIP/Postal Code
00168
Country
Italy
Facility Name
Novartis Investigative Site
City
Cava Dei Tirreni
State/Province
SA
ZIP/Postal Code
84013
Country
Italy
Facility Name
Novartis Investigative Site
City
Siena
State/Province
SI
ZIP/Postal Code
53100
Country
Italy
Facility Name
Novartis Investigative Site
City
Teramo
State/Province
TE
ZIP/Postal Code
64100
Country
Italy
Facility Name
Novartis Investigative Site
City
Orbassano
State/Province
TO
ZIP/Postal Code
10043
Country
Italy
Facility Name
Novartis Investigative Site
City
Trieste
State/Province
TS
ZIP/Postal Code
34149
Country
Italy
Facility Name
Novartis Investigative Site
City
Cuasso al Monte
State/Province
VA
ZIP/Postal Code
21050
Country
Italy
Facility Name
Novartis Investigative Site
City
Verona
State/Province
VR
ZIP/Postal Code
37126
Country
Italy
Facility Name
Novartis Investigative Site
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Facility Name
Novartis Investigative Site
City
Pisa
ZIP/Postal Code
56124
Country
Italy
Facility Name
Novartis Investigative Site
City
Riga
State/Province
LV
ZIP/Postal Code
LV-1038
Country
Latvia
Facility Name
Novartis Investigative Site
City
Riga
ZIP/Postal Code
1002
Country
Latvia
Facility Name
Novartis Investigative Site
City
Kaunas
ZIP/Postal Code
44320
Country
Lithuania
Facility Name
Novartis Investigative Site
City
Klaipeda
ZIP/Postal Code
LT-92231
Country
Lithuania
Facility Name
Novartis Investigative Site
City
Siauliai
ZIP/Postal Code
LT-76231
Country
Lithuania
Facility Name
Novartis Investigative Site
City
Utena
ZIP/Postal Code
LT-28151
Country
Lithuania
Facility Name
Novartis Investigative Site
City
Vilnius
ZIP/Postal Code
LT-08661
Country
Lithuania
Facility Name
Novartis Investigative Site
City
Pachuca
State/Province
Hidalgo
ZIP/Postal Code
42090
Country
Mexico
Facility Name
Novartis Investigative Site
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44100
Country
Mexico
Facility Name
Novartis Investigative Site
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44280
Country
Mexico
Facility Name
Novartis Investigative Site
City
Monterrey
State/Province
Nuevo León
ZIP/Postal Code
64450
Country
Mexico
Facility Name
Novartis Investigative Site
City
San Luis Potosí
ZIP/Postal Code
78218
Country
Mexico
Facility Name
Novartis Investigative Site
City
Almelo
ZIP/Postal Code
7609 PP
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Breda
ZIP/Postal Code
4819 EV
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Eindhoven
ZIP/Postal Code
5623 EJ
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Enschede
ZIP/Postal Code
7513 ER
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Rotterdam
ZIP/Postal Code
3045 PM
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Sneek
ZIP/Postal Code
8601 ZK
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Zwolle
ZIP/Postal Code
8011 JW
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Cercado de Lima
State/Province
Lima
ZIP/Postal Code
01
Country
Peru
Facility Name
Novartis Investigative Site
City
Jesus Maria
State/Province
Lima
ZIP/Postal Code
11
Country
Peru
Facility Name
Novartis Investigative Site
City
La Victoria
State/Province
Lima
ZIP/Postal Code
13
Country
Peru
Facility Name
Novartis Investigative Site
City
Miraflores
State/Province
Lima
ZIP/Postal Code
18
Country
Peru
Facility Name
Novartis Investigative Site
City
San Borja
State/Province
Lima
ZIP/Postal Code
41
Country
Peru
Facility Name
Novartis Investigative Site
City
San Isidro
State/Province
Lima
ZIP/Postal Code
27
Country
Peru
Facility Name
Novartis Investigative Site
City
San Martin de Porres
State/Province
Lima
ZIP/Postal Code
31
Country
Peru
Facility Name
Novartis Investigative Site
City
San Miguel
State/Province
Lima
ZIP/Postal Code
32
Country
Peru
Facility Name
Novartis Investigative Site
City
Santiago de Surco
State/Province
Lima
ZIP/Postal Code
33
Country
Peru
Facility Name
Novartis Investigative Site
City
Quezon City
State/Province
Metro Manila
ZIP/Postal Code
1104
Country
Philippines
Facility Name
Novartis Investigative Site
City
Quezon City
State/Province
Metro Manila
ZIP/Postal Code
1109
Country
Philippines
Facility Name
Novartis Investigative Site
City
Quezon City
ZIP/Postal Code
1100
Country
Philippines
Facility Name
Novartis Investigative Site
City
Quezon City
ZIP/Postal Code
1101
Country
Philippines
Facility Name
Novartis Investigative Site
City
Gdansk
ZIP/Postal Code
80-169
Country
Poland
Facility Name
Novartis Investigative Site
City
Gdansk
ZIP/Postal Code
80-847
Country
Poland
Facility Name
Novartis Investigative Site
City
Katowice
ZIP/Postal Code
40-752
Country
Poland
Facility Name
Novartis Investigative Site
City
Krakow
ZIP/Postal Code
31-159
Country
Poland
Facility Name
Novartis Investigative Site
City
Krakow
ZIP/Postal Code
31-202
Country
Poland
Facility Name
Novartis Investigative Site
City
Krakow
ZIP/Postal Code
31-455
Country
Poland
Facility Name
Novartis Investigative Site
City
Warszawa
ZIP/Postal Code
01-138
Country
Poland
Facility Name
Novartis Investigative Site
City
Warszawa
ZIP/Postal Code
02-341
Country
Poland
Facility Name
Novartis Investigative Site
City
Wroclaw
ZIP/Postal Code
50-044
Country
Poland
Facility Name
Novartis Investigative Site
City
Amadora
ZIP/Postal Code
2720-276
Country
Portugal
Facility Name
Novartis Investigative Site
City
Coimbra
ZIP/Postal Code
3000-075
Country
Portugal
Facility Name
Novartis Investigative Site
City
Coimbra
ZIP/Postal Code
3041-853
Country
Portugal
Facility Name
Novartis Investigative Site
City
Lisboa
ZIP/Postal Code
1169-024
Country
Portugal
Facility Name
Novartis Investigative Site
City
Lisboa
ZIP/Postal Code
1649-035
Country
Portugal
Facility Name
Novartis Investigative Site
City
Lisboa
ZIP/Postal Code
1769-001
Country
Portugal
Facility Name
Novartis Investigative Site
City
Porto
ZIP/Postal Code
4200-319
Country
Portugal
Facility Name
Novartis Investigative Site
City
Bucharest
State/Province
District 3
ZIP/Postal Code
030303
Country
Romania
Facility Name
Novartis Investigative Site
City
Brasov
State/Province
Jud. Brasov
ZIP/Postal Code
500118
Country
Romania
Facility Name
Novartis Investigative Site
City
Constanta
State/Province
Jud. Constanta
ZIP/Postal Code
900002
Country
Romania
Facility Name
Novartis Investigative Site
City
Iasi
State/Province
Jud. Iasi
ZIP/Postal Code
700115
Country
Romania
Facility Name
Novartis Investigative Site
City
Bucharest
ZIP/Postal Code
060011
Country
Romania
Facility Name
Novartis Investigative Site
City
Cluj-Napoca
ZIP/Postal Code
400371
Country
Romania
Facility Name
Novartis Investigative Site
City
Kazan
State/Province
Tatarstan Republic
ZIP/Postal Code
420015
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Chelyabinsk
ZIP/Postal Code
454021
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Chelyabinsk
ZIP/Postal Code
454047
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Ekaterinburg
ZIP/Postal Code
620109
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Ekaterinburg
ZIP/Postal Code
620219
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Kazan
ZIP/Postal Code
420015
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
105077
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
105229
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
115280
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
115446
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
119992
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
121359
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
121609
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Samara
ZIP/Postal Code
443079
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Sankt-Peterburg
ZIP/Postal Code
197022
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
St. Petersburg
ZIP/Postal Code
194354
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
St.-Petersburg
ZIP/Postal Code
193231
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Bratislava
State/Province
Slovak Republic
ZIP/Postal Code
821 06
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Kosice
State/Province
Slovak Republic
ZIP/Postal Code
041 90
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Spisska Nova Ves
State/Province
Slovak Republic
ZIP/Postal Code
052 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Bratislava
ZIP/Postal Code
826 06
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Kosice
ZIP/Postal Code
040 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Lucenec
ZIP/Postal Code
984 39
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Nove Zamky
ZIP/Postal Code
940 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Poprad
ZIP/Postal Code
058 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Bloemfontein
ZIP/Postal Code
9301
Country
South Africa
Facility Name
Novartis Investigative Site
City
Bloemfontein
ZIP/Postal Code
9317
Country
South Africa
Facility Name
Novartis Investigative Site
City
Cape Town
ZIP/Postal Code
8001
Country
South Africa
Facility Name
Novartis Investigative Site
City
Durban
ZIP/Postal Code
4001
Country
South Africa
Facility Name
Novartis Investigative Site
City
Jerez de La Frontera
State/Province
Andalucia
ZIP/Postal Code
11407
Country
Spain
Facility Name
Novartis Investigative Site
City
Malaga
State/Province
Andalucia
ZIP/Postal Code
29010
Country
Spain
Facility Name
Novartis Investigative Site
City
Sanlúcar de Barrameda
State/Province
Andalucia
ZIP/Postal Code
11540
Country
Spain
Facility Name
Novartis Investigative Site
City
Sevilla
State/Province
Andalucia
ZIP/Postal Code
41009
Country
Spain
Facility Name
Novartis Investigative Site
City
Gijon
State/Province
Asturias
ZIP/Postal Code
33290
Country
Spain
Facility Name
Novartis Investigative Site
City
Illescas
State/Province
Castilla la Mancha
ZIP/Postal Code
45200
Country
Spain
Facility Name
Novartis Investigative Site
City
Valladolid
State/Province
Castilla y Leon
ZIP/Postal Code
47011
Country
Spain
Facility Name
Novartis Investigative Site
City
Barcelona
State/Province
Cataluña
ZIP/Postal Code
08003
Country
Spain
Facility Name
Novartis Investigative Site
City
Barcelona
State/Province
Cataluña
ZIP/Postal Code
08036
Country
Spain
Facility Name
Novartis Investigative Site
City
Barcelona
State/Province
Cataluña
ZIP/Postal Code
08041
Country
Spain
Facility Name
Novartis Investigative Site
City
Salt
State/Province
Cataluña
ZIP/Postal Code
17190
Country
Spain
Facility Name
Novartis Investigative Site
City
Sant Boi de Llobregat
State/Province
Cataluña
ZIP/Postal Code
08830
Country
Spain
Facility Name
Novartis Investigative Site
City
Terrassa
State/Province
Cataluña
ZIP/Postal Code
08221
Country
Spain
Facility Name
Novartis Investigative Site
City
Vic
State/Province
Cataluña
ZIP/Postal Code
08500
Country
Spain
Facility Name
Novartis Investigative Site
City
Alicante
State/Province
Comunidad Valenciana
ZIP/Postal Code
03114
Country
Spain
Facility Name
Novartis Investigative Site
City
Alzira
State/Province
Comunidad Valenciana
ZIP/Postal Code
46600
Country
Spain
Facility Name
Novartis Investigative Site
City
Requena
State/Province
Comunidad Valenciana
ZIP/Postal Code
46340
Country
Spain
Facility Name
Novartis Investigative Site
City
Caceres
State/Province
Extremadura
ZIP/Postal Code
10003
Country
Spain
Facility Name
Novartis Investigative Site
City
Mérida
State/Province
Extremadura
ZIP/Postal Code
06800
Country
Spain
Facility Name
Novartis Investigative Site
City
Plasencia
State/Province
Extremadura
ZIP/Postal Code
10600
Country
Spain
Facility Name
Novartis Investigative Site
City
La Coruna
State/Province
Galicia
ZIP/Postal Code
15006
Country
Spain
Facility Name
Novartis Investigative Site
City
Lugo
State/Province
Galicia
ZIP/Postal Code
27003
Country
Spain
Facility Name
Novartis Investigative Site
City
Santiago de Compostela
State/Province
Galicia
ZIP/Postal Code
15706
Country
Spain
Facility Name
Novartis Investigative Site
City
Pozuelo de Alarcón
State/Province
Madrid
ZIP/Postal Code
28223
Country
Spain
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Novartis Investigative Site
City
Göteborg
ZIP/Postal Code
412 63
Country
Sweden
Facility Name
Novartis Investigative Site
City
Göteborg
ZIP/Postal Code
413 45
Country
Sweden
Facility Name
Novartis Investigative Site
City
Luleå
ZIP/Postal Code
SE-971 80
Country
Sweden
Facility Name
Novartis Investigative Site
City
Lund
ZIP/Postal Code
SE-221 85
Country
Sweden
Facility Name
Novartis Investigative Site
City
Malmö
ZIP/Postal Code
205 02
Country
Sweden
Facility Name
Novartis Investigative Site
City
Skellefteå
ZIP/Postal Code
SE 931 32
Country
Sweden
Facility Name
Novartis Investigative Site
City
Stockholm
ZIP/Postal Code
S-171 76
Country
Sweden
Facility Name
Novartis Investigative Site
City
Sundsvall
ZIP/Postal Code
851 86
Country
Sweden
Facility Name
Novartis Investigative Site
City
Faltigberg-Wald
State/Province
ZH
ZIP/Postal Code
8639
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Bern
ZIP/Postal Code
3013
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Crans-Montana
ZIP/Postal Code
3963
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Lausanne
ZIP/Postal Code
1011
Country
Switzerland
Facility Name
Novartis Investigative Site
City
St. Gallen
ZIP/Postal Code
9007
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Thun
ZIP/Postal Code
3600
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Winterthur
ZIP/Postal Code
8401
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Zuerich
ZIP/Postal Code
8032
Country
Switzerland
Facility Name
Novartis Investigative Site
City
Taichung
ZIP/Postal Code
40447
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Taichung
ZIP/Postal Code
40705
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Taipei County
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Taipei
ZIP/Postal Code
10002
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Taipei
ZIP/Postal Code
110
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand
Facility Name
Novartis Investigative Site
City
Chiang Mai
ZIP/Postal Code
50200
Country
Thailand
Facility Name
Novartis Investigative Site
City
Khon Kaen
ZIP/Postal Code
40002
Country
Thailand
Facility Name
Novartis Investigative Site
City
Songkla
ZIP/Postal Code
90110
Country
Thailand
Facility Name
Novartis Investigative Site
City
Ankara
ZIP/Postal Code
06100
Country
Turkey
Facility Name
Novartis Investigative Site
City
Canakkale
ZIP/Postal Code
17100
Country
Turkey
Facility Name
Novartis Investigative Site
City
Diskapi / Ankara
ZIP/Postal Code
06110
Country
Turkey
Facility Name
Novartis Investigative Site
City
Emek / Ankara
ZIP/Postal Code
06510
Country
Turkey
Facility Name
Novartis Investigative Site
City
Gaziantep
ZIP/Postal Code
27070
Country
Turkey
Facility Name
Novartis Investigative Site
City
Isparta
ZIP/Postal Code
32100
Country
Turkey
Facility Name
Novartis Investigative Site
City
Istanbul
Country
Turkey
Facility Name
Novartis Investigative Site
City
Izmir
ZIP/Postal Code
35340
Country
Turkey
Facility Name
Novartis Investigative Site
City
Kahramanmaras
ZIP/Postal Code
46100
Country
Turkey
Facility Name
Novartis Investigative Site
City
Kecioren / Ankara
ZIP/Postal Code
06280
Country
Turkey
Facility Name
Novartis Investigative Site
City
Kozlu / Zonguldak
ZIP/Postal Code
67600
Country
Turkey
Facility Name
Novartis Investigative Site
City
Malatya
ZIP/Postal Code
44280
Country
Turkey
Facility Name
Novartis Investigative Site
City
Mersin
ZIP/Postal Code
33079
Country
Turkey
Facility Name
Novartis Investigative Site
City
Yenisehir/Izmir
ZIP/Postal Code
35110
Country
Turkey
Facility Name
Novartis Investigative Site
City
Swansea
State/Province
England
ZIP/Postal Code
SA6 6NL
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Newcastle Upon Tyne
State/Province
Newcastle
ZIP/Postal Code
NE7 7DN
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Ash Vale
State/Province
Surrey
ZIP/Postal Code
GU12 5BA
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Crawley
State/Province
West Sussex
ZIP/Postal Code
RH10 7DX
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Belfast
ZIP/Postal Code
BT7 2BE
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Bexhill-on-Sea
ZIP/Postal Code
TN40 1JJ
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Bradford
ZIP/Postal Code
BD9 6RJ
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Bristol
ZIP/Postal Code
BS10 5NB
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Cambridge
ZIP/Postal Code
CB7 5JD
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Lancashire
ZIP/Postal Code
B13 6TL
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Lancashire
ZIP/Postal Code
FY3 7EN
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Liverpool
ZIP/Postal Code
L9 7AL
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
London
ZIP/Postal Code
E2 9JX
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
London
ZIP/Postal Code
SW3 6PH
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
London
ZIP/Postal Code
W1G 8HU
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Newport
ZIP/Postal Code
P030 5TG
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Stockport
ZIP/Postal Code
SK4 4NX
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Stockport
ZIP/Postal Code
SK8 6LU
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Surrey
ZIP/Postal Code
KT16 0PZ
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Warminster
ZIP/Postal Code
BA12 9AA
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Watford
ZIP/Postal Code
WD25 0EA
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Windsor
ZIP/Postal Code
SL4 3DP
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Valencia
State/Province
Estado Carabobo
ZIP/Postal Code
2005
Country
Venezuela
Facility Name
Novartis Investigative Site
City
Barquisimeto
State/Province
Estado Lara
ZIP/Postal Code
3002
Country
Venezuela
Facility Name
Novartis Investigative Site
City
Maracaibo
State/Province
Estado Zulia
ZIP/Postal Code
4002
Country
Venezuela

12. IPD Sharing Statement

Citations:
PubMed Identifier
24461613
Citation
Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, Cameron R, Shoaib M, Lawrence D, Young D, McBryan D; INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013 Sep;1(7):524-33. doi: 10.1016/S2213-2600(13)70158-9. Epub 2013 Aug 21.
Results Reference
derived

Learn more about this trial

Exacerbation Study

We'll reach out to this number within 24 hrs